Kestra Medical Technologies (NASDAQ:KMTS) Stock Rating Upgraded by Wall Street Zen

Posted by Stanley Muller on Aug 10th, 2026

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

KMTS has been the subject of several other research reports. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, BTIG Research raised their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $27.83.

Read Our Latest Analysis on Kestra Medical Technologies

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS opened at $26.40 on Friday. The firm has a 50 day simple moving average of $22.96 and a 200-day simple moving average of $22.57. Kestra Medical Technologies has a twelve month low of $14.30 and a twelve month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.55 billion, a PE ratio of -10.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. On average, equities analysts predict that Kestra Medical Technologies will post -2.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Traci S. Umberger sold 8,752 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $22.60, for a total transaction of $197,795.20. Following the completion of the sale, the insider owned 206,995 shares in the company, valued at approximately $4,678,087. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alfred J. Ford, Jr. sold 13,015 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $23.90, for a total value of $311,058.50. Following the transaction, the insider directly owned 105,839 shares in the company, valued at approximately $2,529,552.10. This represents a 10.95% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 211,877 shares of company stock valued at $4,922,844 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in KMTS. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies in the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. raised its stake in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period. Daiwa Securities Group Inc. purchased a new position in Kestra Medical Technologies in the 4th quarter valued at $72,000. Finally, Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the last quarter.

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.